References
- Ozaki M, Matsuda M, Tomii Y et al. In vitro antibacteri-al activity of a new quinolone, NM441. Antimicrob Agents Chemother 1991; 35 (12): 2490-2495.
- Ozaki M, Matsuda M, Tomii Y et al. In vivo evaluation of NM441, a new thiazeto-quinoline derivative. Antimicrob Agents Chemother 1991; 35 (12): 2496-2499.
- Nakashima M, Uematsu T, Kosuge K et al. Pharmacokinetics and safety of NM441, a new quinolone, in healthy male volunteers. J Clin Pharmacol 1994; 34 (9): 930-937.
- Yoshida T, Mitsuhashi S. Antibacterial activity of NM394, the active form of prodrug NM441, a new quinolone. Antimicrob Agents Chemother 1993; 37 (4): 793–800.
- Montanan i MP, Mingoia M, Varaldo PE. In vitro antibac-terial activities of AF 3013, the active metabolite of prulifloxacin, against nosocomial and community Italian iso-lates. Antimicrob Agents Chemother 2001; 45 (12): 3616–3622.
- Prats G, Roig C, Mixt) E, Navarro F, Mirelis B. In vitro activity of the active metabolite of prulifloxacin (AF 3013) compared with six other fluoroquinolones. Eur J Clin Microbiol Infect Dis 2002; 21 (4): 328–334.
- Keam SJ, Perry CM. Prulifloxacin. Drugs 2004; 64 (19), 2221–2234.
- Fattore C, Cipolla G, Gatti G et al. Pharmacokinetic interactions between theophylline and prulifloxacin in healthy volunteers. Clin Drug Invest 1998; 16 (5): 387–392.
- Picollo R, Brion N, Gualano V et al. Pharmacokinetics and tolerability of prulifloxacin after single oral administration. Arzneim-Forsch/Drug Res 2003; 53 (3): 201–205.
- Angelini ACRAF S.p.A. Investigator's brochure: Unidrox® prulifloxacin 600 mg tablets. Rome: ACRAF S.p.A. 2004.
- National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacte-ria that grow aerobically. 6th ed. Approved standard M7-A6. Wayne, PA: NCCLS 2003.
- National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests. 8th ed. Approved standard M2-A8. Wayne, PA: NCCLS 2003.
- National Committee for Clinical Laboratory Standards. Development of in vitro susceptibility testing criteria and qual-ity control parameters. 2nd ed. Approved standard M23-A2. Wayne, PA: NCCLS 2001.
- Fuchs PC, Barry AL, Brown SD. Selection of zone size interpretive criteria for disk diffusion susceptibility tests of three antibiotics against Streptococcus pneumoniae, using the new guidelines of the National Committee for Clinical Laboratory Standards. Antimicrob Agents Chemother 2002; 46 (2): 398–401.
- Metzler DM, DeHaan RM. Susceptibility test of anaero-bic bacteria: statistical and clinical considerations. J Infect Dis 1974; 130 (6): 588–594.
- Brunden MN, Zurenko GE, Kapik B. Modification of the error-bounded classification scheme for use with two MIC breakpoints. Diagn Microbiol Infect Dis 1992; 15 (2): 135–140.
- National Committee for Clinical Laboratory Standards. Development of in vitro susceptibility testing criteria and qual-ity control parameters. Approved standard M23-A. Villanova, PA: NCCLS 1994.